​

Maze Therapeutics (MAZE) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChart

MAZE Stock Forecast

Maze Therapeutics (MAZE) stock forecast, based on 6 Wall Street analysts, predicts a 12-month average price target of $69.00, with a high of $97.00 and a low of $46.00. This represents a 120.73% increase from the last price of $31.26.

MAZE Stock Rating

Maze Therapeutics stock's rating consensus is Buy, based on 6 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 6 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 6 0 6 Strong Sell Sell Hold Buy Strong Buy

MAZE Price Target Upside V Benchmarks

TypeNameUpside
StockMaze Therapeutics120.73%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts-111
Avg Price Target-$64.00$51.36
Last Closing Price$31.26$31.26$31.26
Upside/Downside-104.73%64.30%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jul, 26111---12
Jun, 26111---12
May, 26111---12
Apr, 26111---12
Mar, 2619---10
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Apr 14, 2026Truist Financial$64.00$27.42133.41%104.73%
Mar 17, 2026Danielle BrillTruist Financial$68.00$50.3934.95%117.53%
Jan 19, 2026BTIG$46.00$40.7712.83%47.15%
Dec 19, 2025Debjit ChattopadhyayGuggenheim$46.00$41.929.73%47.15%
Dec 04, 2025Wells Fargo$55.00$41.4932.56%75.94%
Dec 03, 2025H.C. Wainwright$60.00$38.7554.84%91.94%
Nov 13, 2025Raymond James$48.00$31.8450.75%53.55%
Sep 15, 2025Debjit ChattopadhyayGuggenheim$34.00$23.2546.24%8.77%
Sep 02, 2025BTIG$30.00$15.3295.82%-4.03%
Jul 08, 2025Laura ChicoWedbush$17.00$13.3127.72%-45.62%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Mar 25, 2026Raymond JamesStrong BuyStrong Buyhold
Mar 25, 2026H.C. WainwrightBuyBuyhold
Jan 28, 2026H.C. WainwrightBuyBuyhold
Jan 19, 2026BTIGBuyBuyhold
Dec 19, 2025GuggenheimBuyBuyhold
Dec 04, 2025Wells FargoOverweightinitialise
Dec 03, 2025H.C. WainwrightBuyBuyhold
Nov 13, 2025Raymond JamesStrong Buyinitialise
Sep 15, 2025GuggenheimBuyBuyhold
Sep 12, 2025H.C. WainwrightBuyBuyhold

Financial Forecast

EPS Forecast

$-20 $-15 $-10 $-5 $0 $5 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28 Dec 29
Dec 24Dec 25Dec 26Dec 27Dec 28Dec 29
Reported$0.08$-3.05----
Avg Forecast$-7.88$-2.69$-2.76$-3.01$-3.04$-2.93
High Forecast$0.10$-2.61$-2.71$-2.38$-3.04$-2.93
Low Forecast$-15.86$-2.77$-2.81$-3.59$-3.04$-2.93
Surprise %-101.02%13.38%----

Revenue Forecast

$0 $40M $80M $120M $160M $200M Dec 24 Dec 25 Dec 26 Dec 27 Dec 28 Dec 29
Dec 24Dec 25Dec 26Dec 27Dec 28Dec 29
Reported$167.50M-----
Avg Forecast$167.67M$3.13M$167.50M$6.25M$6.25M$90.00M
High Forecast$167.75M$3.13M$167.50M$6.25M$6.25M$90.00M
Low Forecast$167.58M$3.13M$167.50M$6.25M$6.25M$90.00M
Surprise %-0.10%-----

Net Income Forecast

$-700M $-540M $-380M $-220M $-60M $100M Dec 24 Dec 25 Dec 26 Dec 27 Dec 28 Dec 29
Dec 24Dec 25Dec 26Dec 27Dec 28Dec 29
Reported$52.23M$-131.12M----
Avg Forecast$3.40M$-117.88M$-120.81M$-130.78M$-133.08M$-128.27M
High Forecast$4.37M$-114.46M$-118.54M$-104.22M$-133.08M$-128.27M
Low Forecast$-694.51M$-121.29M$-123.08M$-157.35M$-133.08M$-128.27M
Surprise %1433.95%11.24%----

MAZE Forecast FAQ

Is Maze Therapeutics stock a buy?

Maze Therapeutics stock has a consensus rating of Buy, based on 6 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 6 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Maze Therapeutics is a favorable investment for most analysts.

What is Maze Therapeutics's price target?

Maze Therapeutics's price target, set by 6 Wall Street analysts, averages $69 over the next 12 months. The price target range spans from $46 at the low end to $97 at the high end, suggesting a potential 120.73% change from the previous closing price of $31.26.

How does Maze Therapeutics stock forecast compare to its benchmarks?

Maze Therapeutics's stock forecast shows a 120.73% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Maze Therapeutics over the past three months?

  • July 2026: 8.33% Strong Buy, 91.67% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • June 2026: 8.33% Strong Buy, 91.67% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • May 2026: 8.33% Strong Buy, 91.67% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Maze Therapeutics’s EPS forecast?

Maze Therapeutics's average annual EPS forecast for its fiscal year ending in December 2026 is $-2.76, marking a -9.51% decrease from the reported $-3.05 in 2025. Estimates for the following years are $-3.01 in 2027, $-3.04 in 2028, and $-2.93 in 2029.

What is Maze Therapeutics’s revenue forecast?

Maze Therapeutics's average annual revenue forecast for its fiscal year ending in December 2026 is $167.5M, reflecting a 0% decrease from the reported $0 in 2025. The forecast for 2027 is $6.25M, followed by $6.25M for 2028, and $90M for 2029.

What is Maze Therapeutics’s net income forecast?

Maze Therapeutics's net income forecast for the fiscal year ending in December 2026 stands at $-121M, representing a -7.86% decrease from the reported $-131M in 2025. Projections indicate $-131M in 2027, $-133M in 2028, and $-128M in 2029.